Document Detail

Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
MedLine Citation:
PMID:  14555308     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVES: Flow cytometry enumeration of peripheral blood CD34-positive cells provides reliable measurements of circulating hematopoietic progenitors in humans. Since the absolute number of circulating CD34-positive cells has been previously found to be elevated in myelofibrosis with myeloid metaplasia (MMM), we prospectively studied the clinical utility of this parameter in the work-up of patients with chronic myeloproliferative disorders. DESIGN AND METHODS: Of the 248 consecutive patients enrolled in this study, 106 had polycythemia vera (PV), 90 essential thrombocythemia (ET), and 52 myelofibrosis with myeloid metaplasia (MMM). The study population included both newly diagnosed and established cases, and of these latter some patients were on cytoreductive treatment while others were chemotherapy naive. Both cross-sectional and longitudinal investigations were carried out. Flow cytometry enumeration of CD34-positive cells was performed using a single-platform assay. RESULTS: Median numbers and ranges of circulating CD34-positive cells were 2.3x10(6)/L (0-5) in 20 control subjects, 2.2x10(6)/L (0-14) in those with PV, 2.4x10(6)/L (0-14) in those with ET, and 114x10(6)/L (6-2,520) in MMM patients. Analysis of variance demonstrated that values were markedly higher in MMM patients than in the remaining groups, and counts did not appear to fluctuate over short periods of follow-up. In both cross-sectional and longitudinal investigations on patients at clinical onset and/or out of cytoreductive treatment, a CD34-positive count of > or = 15x10(6)/L was always associated with MMM, clearly indicating a disease-related specificity. INTERPRETATION AND CONCLUSIONS: The absolute number of circulating CD34-positive cells is normal or anyhow lower than 15x10(6)/L in patients with uncomplicated PV or ET, whereas it is equal or above this cut-off in those with MMM, likely reflecting abnormal hematopoietic progenitor cell trafficking. Thus, enumeration of circulating CD34-positive cells may be useful in the work-up of patients with myeloproliferative disorders.
Francesco Passamonti; Laura Vanelli; Lucia Malabarba; Elisa Rumi; Ester Pungolino; Luca Malcovati; Cristiana Pascutto; Enrica Morra; Mario Lazzarino; Mario Cazzola
Related Documents :
8822938 - Persistence of the aml1/eto fusion transcript in patients treated with allogeneic bone ...
18760708 - The expanding role of arsenic in acute promyelocytic leukemia.
21871938 - Does high-resolution donor typing of hla-c or other loci upon registration confer advan...
2804348 - Diffuse osteosclerosis in hairy cell leukemia.
2147018 - The information value of clinical data.
10999088 - Evaluation of csf-adenosine deaminase activity in tubercular meningitis.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Haematologica     Volume:  88     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-13     Completed Date:  2004-09-30     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1123-9     Citation Subset:  IM    
Division of Hematology, University of Pavia Medical School & IRCCS Policlinico S. Matteo, Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antigens, CD34 / blood*,  metabolism*
Biological Markers / blood
Cell Count
Cross-Sectional Studies
Hematopoietic Stem Cells / metabolism*
Longitudinal Studies
Middle Aged
Myeloproliferative Disorders / blood*
Polycythemia Vera / blood
Primary Myelofibrosis / blood
Prospective Studies
Thrombocythemia, Essential / blood
Reg. No./Substance:
0/Antigens, CD34; 0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to inter...
Next Document:  Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with t...